Westerveld HE, Hoogendoorn M, de Jong AWF, Goverde AJ, Fauser BCJM, Dallinga-Thie GM. Cardiometabolic abnormalities in the polycystic ovary syndrome: Pharmacotherapeutic insights. Pharmacol Ther. 2008;119(3):223–41.
Glintborg D, Rubin KH, Nybo M, Abrahamsen B, Andersen M. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol [Internet]. 2018;17(1):1–12. Available from: https://doi.org/10.1186/s12933-018-0680-5
Wild RA. Dyslipidemia in PCOS. Steroids [Internet]. 2012;77(4):295–9. Available from: http://dx.doi.org/10.1016/j.steroids.2011.12.002
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia: REDUCE-IT. N Engl J Med. 2019;380(1):11–22.
Johnson NP. Metformin use in women with polycystic ovary syndrome. Ann Transl Med. 2014;2(6):1–6.
Björnson E. Packard CJ, Adiels M, Andersson L, Matikainen N, Kahri J. Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects. J Intern Med. 2019;1–17.
For membership questions and public speaking enquiries, please get in touch